Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 5/20 | 0.46 |
| ▸ | KDR | P35968 | 5/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.41 |
| ▸ | LPL | P06858 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | WNT3A | P56704 | 2/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12517907 | 0.85 | PRMT5 (0.43) | PDGFRBKDRHIF1ADGAT1 | |
| SCHEMBL2222243 | 0.82 | DGAT1 (0.41) | PDGFRBKDRLIPGLPLHIF1A | |
| SCHEMBL7139795 | 0.81 | CA1 (0.48) | PDGFRBKDRLIPGLPLHIF1A | |
| SCHEMBL12517468 | 0.78 | ALPL (0.38) | PDGFRBKDRLIPGLPLHIF1A | |
| SCHEMBL13275056 | 0.78 | LIPG (0.49) | PDGFRBKDRLIPGLPLP4HB | |
| SCHEMBL13274901 | 0.77 | LIPG (0.40) | PDGFRBKDRLIPGLPLHIF1A | |
| SCHEMBL255643 | 0.76 | CLK4 (0.44) | PDGFRBLIPGLPLCA1CA2 | |
| SCHEMBL19436732 | 0.75 | LIPG (0.46) | PDGFRBKDRLIPGLPLP4HB | |
| SCHEMBL1950009 | 0.75 | CDK8 (0.46) | PDGFRBKDRCA1CA2CA9 | |
| SCHEMBL18340958 | 0.74 | LIPG (0.40) | PDGFRBKDRLIPGLPLHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2515657-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | PDGFRB 84/4885KDR 131/4885LIPG 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.